Shanghai Hanmai Biopharmaceutical Technology

Shanghai Hanmai Biopharmaceutical Technology is a Chinese biotechnology company and a subsidiary of PegBio. The company focuses on the development of innovative therapeutics for chronic and metabolic diseases, specifically leveraging PEGylation technology to improve drug performance. Its lead candidate, PB-1902, is an oral selective opioid receptor antagonist designed to treat opioid-induced constipation (OIC). Shanghai Hanmai operates as a key research and development unit within the PegBio group, which is known for its long-acting GLP-1 receptor agonists. The company is headquartered in the Shanghai Pilot Free Trade Zone and maintains a pipeline focused on addressing significant unmet medical needs in gastroenterology and metabolic health. By utilizing advanced chemical modification techniques, the company aims to enhance the efficacy and safety profiles of small molecule therapeutics.